A Non-inferiority Study on Dose Reduction of Adalimumab in Psoriasis Patients Who Are Overtreated
NCT ID: NCT05683054
Last Updated: 2023-01-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
19 participants
INTERVENTIONAL
2020-08-11
2022-08-22
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Dose Tapering Study of Adalimumab in Psoriasis
NCT04028713
Therapeutic Drug Monitoring of Adalimumab in Psoriasis Patients
NCT02147600
Prevalence and Incidence of Articular Symptoms and Signs Related to Psoriatic Arthritis in Patients With Psoriasis Severe or Moderate With Adalimumab Treatment
NCT01316224
Study of Two Dosing Schedules of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis
NCT00645905
Therapeutic Drug Monitoring of Tildrakizumab in Psoriasis Patients
NCT05683015
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Before randomization, 3 subsequent evaluations of adalimumab Ctroughs will be executed. Patients will be included after signing informed consent and randomized if 2/3 subsequent measurements during screening show supratherapeutic Ctrough levels. Time point of randomization is considered baseline (week 0). PASI calculation will be performed by a blinded and independent physician.
In the concentration based arm, dosing frequency will be lowered to 40 mg every 3 weeks (33% reduction). In case of persistent supratherapeutic Ctroughs, a 50% dose reduction will be applied from week 12 onwards. In the standard based arm, patients will continue on standard dosing schedule of 40 mg every other week.
During each study visit PASI and IGA score will be evaluated by an independent and blinded physician and adverse events, and concomitant medications will be evaluated by a member of the study team. Ctrough is quantified at each visit; and anti-drug antibodies concentrations only if subtherapeutic concentrations are observed. Patients complete the Dermatology Life Quality Index (DLQI) and EuroQol-5D-5L instrument at each visit.
In addition, in a subset of patients in each treatment arm, additional sampling will be collected by dried blood spot sampling in order to build a PK(PD) model for adalimumab,
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Standard dosing group
In the standard based arm, patients will continue to receive adalimumab according to the standard dosing schedule of 40 mg every other week (maintenance phase).
Venapuncture
Blood samples will be collected to determine the serum trough levels and anti-drug antibodies of adalimumab
Dermatology Life Quality Index (DLQI)
The impact of the disease on the patient will be assessed using the dermatology life quality index (DLQI).
EQ-5D-5L questionnaire
The EQ-5D-5L which is a standardized instrument developed by the EuroQol Group as a measure of health-related quality of life that can be used in a wide range of health conditions and treatments will be assessed.
Dried blood spot sampling
A subset of patients will sample additionally by using dried blood sampling after the first drug injection post-inclusion.
Dose tapering group
In the dose tapering arm, adalimumab dosing frequency will be lowered to 40 mg every 3 weeks in patients who have supratherapeutic serum trough levels of adalimumab at three consecutive measurements.
Dose tapering of adalimumab in patients with supratheurapeutic serum trough levels
In the dose tapering arm, adalimumab dosing frequency will be lowered to 40 mg every 3 weeks in patients who have supratherapeutic serum trough levels of adalimumab (33% reduction). If patients still have a good clinical response and supratherapeutic adalimumab serum trough levels, will be further tapered to a dose regimen of 1 subcutaneous injection (40mg) every 4 weeks (50% dose reduction).
Venapuncture
Blood samples will be collected to determine the serum trough levels and anti-drug antibodies of adalimumab
Dermatology Life Quality Index (DLQI)
The impact of the disease on the patient will be assessed using the dermatology life quality index (DLQI).
EQ-5D-5L questionnaire
The EQ-5D-5L which is a standardized instrument developed by the EuroQol Group as a measure of health-related quality of life that can be used in a wide range of health conditions and treatments will be assessed.
Dried blood spot sampling
A subset of patients will sample additionally by using dried blood sampling after the first drug injection post-inclusion.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Dose tapering of adalimumab in patients with supratheurapeutic serum trough levels
In the dose tapering arm, adalimumab dosing frequency will be lowered to 40 mg every 3 weeks in patients who have supratherapeutic serum trough levels of adalimumab (33% reduction). If patients still have a good clinical response and supratherapeutic adalimumab serum trough levels, will be further tapered to a dose regimen of 1 subcutaneous injection (40mg) every 4 weeks (50% dose reduction).
Venapuncture
Blood samples will be collected to determine the serum trough levels and anti-drug antibodies of adalimumab
Dermatology Life Quality Index (DLQI)
The impact of the disease on the patient will be assessed using the dermatology life quality index (DLQI).
EQ-5D-5L questionnaire
The EQ-5D-5L which is a standardized instrument developed by the EuroQol Group as a measure of health-related quality of life that can be used in a wide range of health conditions and treatments will be assessed.
Dried blood spot sampling
A subset of patients will sample additionally by using dried blood sampling after the first drug injection post-inclusion.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Participants must have a diagnosis of chronic plaque-type psoriasis for at least 6 months (with or without PsA), prior to the first administration of study intervention.
3. Participant must remain on a highly effective method of birth control during the study or during the entire treatment with adalimumab (whether with is longer)
4. Participants are considered eligible according to the following TB screening criteria:
* Have no history of latent or active TB before screening
* Have no signs or symptoms suggestive for active TB upon medical history and/or physical examination
* Have had no recent close contact with a person with active TB
5. Participants must agree not to receive a live virus or live bacterial vaccination at least 3 months (or longer as indicated in the package insert of the relevant vaccine) prior to the first administration of study intervention (except for varicella and MMR vaccines), during the study, or within 3 months after the last administration of study intervention.
6. Participants must avoid prolonged sun exposure and use of tanning booths or other ultraviolet light sources during study.
7. Participants must sign an ICF indicating that he or she understands the purpose of, and procedures required for, the study and is willing to participate in the study.
Exclusion Criteria
2. Participants who are pregnant, nursing or planning a pregnancy or fathering a child while enrolled in the study or within 12 weeks after receiving the last administration of study intervention
3. Participants who have received, or are expected to receive, any live virus or bacterial vaccination (with the exception of varicella or MMR vaccines) within 3 months (or longer as indicated in the package insert of the relevant vaccine) prior to the first administration of study intervention, during the study, or within 12 weeks after the last administration of study intervention
4. Participants who have known allergies, hypersensitivity or intolerance to adalimumab or its excipients
5. Participants who have any malignancy or have a history of malignancy
6. Participants who are unable or unwilling to undergo multiple venapunctures
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
KU Leuven
OTHER
University Hospital, Ghent
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jo Lambert, Prof. Dr.
Role: PRINCIPAL_INVESTIGATOR
University Ghent
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital
Ghent, , Belgium
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TDM-ADA2019
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.